

Box No. VIII (ii) DECLARATION: ENTITLEMENT TO APPLY FOR AND BE GRANTED A PATENT

The declaration must conform to the standardized wording provided for in Section 212; see Notes to Boxes Nos. VIII, VIII (i) to (v) (in general) and the specific Notes to Box No. VIII (ii). If this Box is not used, this sheet should not be included in the request.

Declaration as to the applicant's entitlement, as at the international filing date, to apply for and be granted a patent (Rules 4.17(ii) and 51bis.1(a)(ii)), in a case where the declaration under Rule 4.17(iv) is not appropriate:

in relation to this International Application,

GlaxoSmithKline Consumer Healthcare Holdings (US) LLC is entitled to apply for and be granted a patent by virtue of the following:

an assignment from ANDERSON, Gary Bruce to GlaxoSmithKline Consumer Healthcare Holdings (US) LLC dated 18 March 2022

an assignment from BAILEY, Hope Patricia to GlaxoSmithKline Consumer Healthcare Holdings (US) LLC dated 7 March 2022

an assignment from BOGGIA, Jonathon Michael to GlaxoSmithKline Consumer Healthcare Holdings (US) LLC dated 17 March 2022

an assignment from KINTER, Kevin Scott to GlaxoSmithKline Consumer Healthcare Holdings (US) LLC dated 7 March 2022

an assignment from MOORE, Rachel Elizabeth to GlaxoSmithKline Consumer Healthcare Holdings (US) LLC dated 7 March 2022

an assignment from PATEL, Jigna Dhanu to GlaxoSmithKline Consumer Healthcare Holdings (US) LLC dated 16 March 2022

an assignment from PATEL, Shivangi Akash to GlaxoSmithKline Consumer Healthcare Holdings (US) LLC dated 10 March 2022

☐ This declaration is continued on the following sheet, "Continuation of Box No. VIII (ii)".